Cargando…
Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study
This study investigated the clinical efficacy, safety and tolerance of endostatin combined with gemcitabine and carboplatin for patients with advanced nonsmall cell lung cancer (NSCLC). From January 2010 to January 2014, 49 patients with advanced NSCLC were retrospectively evaluated; we defined 2 su...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter Open
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914085/ https://www.ncbi.nlm.nih.gov/pubmed/29696151 http://dx.doi.org/10.1515/med-2018-0022 |
_version_ | 1783316645950783488 |
---|---|
author | Yu, Xun Zhang, Lemeng Chen, Jianhua |
author_facet | Yu, Xun Zhang, Lemeng Chen, Jianhua |
author_sort | Yu, Xun |
collection | PubMed |
description | This study investigated the clinical efficacy, safety and tolerance of endostatin combined with gemcitabine and carboplatin for patients with advanced nonsmall cell lung cancer (NSCLC). From January 2010 to January 2014, 49 patients with advanced NSCLC were retrospectively evaluated; we defined 2 subgroups: a combination group (chemotherapy + anti-angiogenic therapy) and a chemotherapy group (chemotherapy only). The cases in the chemotherapy group received treatment with gemcitabine and carboplatin only, whereas the cases in the combination group received endostatin in combination with gemcitabine and carboplatin. The patients received 2 cycles of treatment (21 days/cycle). The clinical efficacy and adverse events were observed and compared. The disease control rate in the combination group was significantly higher compared with the chemotherapy group (P < 0.05). When comparing the cases of squamous carcinoma, the disease control rate in the combination group was significantly higher than the chemotherapy group (P < 0.05). Moreover, the progression free survival in the combination group was higher than that for the chemotherapy group, with a statistically significant difference (P < 0.05). The combination of endostatin with chemotherapeutic agents is improve to the survival of patients with advanced NSCLC favorably; the adverse events of this regimen are well tolerated. |
format | Online Article Text |
id | pubmed-5914085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | De Gruyter Open |
record_format | MEDLINE/PubMed |
spelling | pubmed-59140852018-04-25 Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study Yu, Xun Zhang, Lemeng Chen, Jianhua Open Med (Wars) Regular Articles This study investigated the clinical efficacy, safety and tolerance of endostatin combined with gemcitabine and carboplatin for patients with advanced nonsmall cell lung cancer (NSCLC). From January 2010 to January 2014, 49 patients with advanced NSCLC were retrospectively evaluated; we defined 2 subgroups: a combination group (chemotherapy + anti-angiogenic therapy) and a chemotherapy group (chemotherapy only). The cases in the chemotherapy group received treatment with gemcitabine and carboplatin only, whereas the cases in the combination group received endostatin in combination with gemcitabine and carboplatin. The patients received 2 cycles of treatment (21 days/cycle). The clinical efficacy and adverse events were observed and compared. The disease control rate in the combination group was significantly higher compared with the chemotherapy group (P < 0.05). When comparing the cases of squamous carcinoma, the disease control rate in the combination group was significantly higher than the chemotherapy group (P < 0.05). Moreover, the progression free survival in the combination group was higher than that for the chemotherapy group, with a statistically significant difference (P < 0.05). The combination of endostatin with chemotherapeutic agents is improve to the survival of patients with advanced NSCLC favorably; the adverse events of this regimen are well tolerated. De Gruyter Open 2018-04-19 /pmc/articles/PMC5914085/ /pubmed/29696151 http://dx.doi.org/10.1515/med-2018-0022 Text en © 2018 Xun Yu et al. http://creativecommons.org/licenses/by-nc-nd/4.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License. |
spellingShingle | Regular Articles Yu, Xun Zhang, Lemeng Chen, Jianhua Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study |
title | Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study |
title_full | Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study |
title_fullStr | Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study |
title_full_unstemmed | Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study |
title_short | Effectiveness of Treatment with Endostatin in Combination with Emcitabine, Carboplatin, and Gemcitabine in Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study |
title_sort | effectiveness of treatment with endostatin in combination with emcitabine, carboplatin, and gemcitabine in patients with advanced non-small cell lung cancer: a retrospective study |
topic | Regular Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914085/ https://www.ncbi.nlm.nih.gov/pubmed/29696151 http://dx.doi.org/10.1515/med-2018-0022 |
work_keys_str_mv | AT yuxun effectivenessoftreatmentwithendostatinincombinationwithemcitabinecarboplatinandgemcitabineinpatientswithadvancednonsmallcelllungcanceraretrospectivestudy AT zhanglemeng effectivenessoftreatmentwithendostatinincombinationwithemcitabinecarboplatinandgemcitabineinpatientswithadvancednonsmallcelllungcanceraretrospectivestudy AT chenjianhua effectivenessoftreatmentwithendostatinincombinationwithemcitabinecarboplatinandgemcitabineinpatientswithadvancednonsmallcelllungcanceraretrospectivestudy |